Skip to main content
NewslettersWatchlist

Biomarin Pharmaceuticals(BMRN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Biomarin Pharmaceuticals

770 Lindaro Street
San Rafael CA 94901 USA
P: 415-506-6700
F: 415-382-7889
http://www.bmrn.com

Profile

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.

Key Executives

NameTitle
Henry J. FuchsPresident, Divisional
G. Eric DavisChief Legal Officer/Executive VP/Secretary
Jeffrey R. AjerExecutive VP/Other Executive Officer
Brian MuellerCFO/Executive VP
Charles Greg GuyerChief Technology Officer/Executive VP
Erin BurkhartChief Accounting Officer/Vice President
Alexander HardyCEO/Director/President

More from The Globe

The close: Wall Street sharply higher as nonfarm payrolls report strengthens case for rate cuts in both the U.S. and Canada
A trader works inside a booth on the floor of the New York Stock Exchange on May 1.
The close: Major North American indexes higher, led by Nasdaq, amid plethora of mixed earnings
Traders work on the floor at the New York Stock Exchange in New York, Wednesday, May 1.
Trump awarded 36 million more Trump Media shares worth $1.8-billion after hitting price benchmarks
Former President Donald Trump speaks to reporters as he leaves the courtroom for the day at Manhattan criminal court, in New York, U.S., April 30, 2024. Seth Wenig/Pool via REUTERS
investor newsletter
The key to successful investing. Plus, why Fairfax Financial is poised for an extraordinary run
investor happy money
The close: Stocks mixed as Fed leaves investors guessing as to when rate cuts will arrive
NEW YORK, NEW YORK - APRIL 29: Traders work on the floor of the New York Stock Exchange during morning trading on April 29, 2024 in New York City. Stocks opened high Monday morning amid a Federal Reserve rate decision and the monthly jobs report later this week. (Photo by Michael M. Santiago/Getty Images)
Tuesday’s analyst upgrades and downgrades
Samuel Drouin-Tardif, an electro-mechanic for Boralex, walks in the snow while looking at a wind turbine in Thetford Mines November 24, 2023.
The close: Major indexes fall after wage data; cannabis shares surge on U.S. regulatory move
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.
The close: Stocks higher as investors focus on Fed moves
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.